IONIS-AGT-LRx

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Chronic Heart Failure With Reduced Ejection Fraction

Drug Information

Target Indication

Chronic Heart Failure With Reduced Ejection Fraction

Clinical Trial

Last updated: 12/8/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

IONS

Ionis Pharmaceuticals, Inc.

Related Pipeline

Angelman Syndrome

Familial Chylomicronemia Syndrome

Familial Chylomicronemia Syndrome

FAP

Amyotrophic Lateral Sclerosis